Cargando…

Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis

Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sang Jin, Kim, Jong Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Liver Cancer Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035684/
https://www.ncbi.nlm.nih.gov/pubmed/37383081
http://dx.doi.org/10.17998/jlc.2021.03.17
_version_ 1784911462577209344
author Kim, Sang Jin
Kim, Jong Man
author_facet Kim, Sang Jin
Kim, Jong Man
author_sort Kim, Sang Jin
collection PubMed
description Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Recently, various studies on locoregional therapies for downstaging followed by living donor liver transplantation reported inspiring overall survival and recurrence-free survival of patients. These downstaging procedures included three-dimensional conformal radiation therapy, trans-arterial chemoembolization, stereotactic body radiation therapy, trans-arterial radioembolization, hepatic arterial infusion chemotherapy and combinations of these therapies. Selection of the optimal downstaging protocol should depend on tumor location, biology and background liver status. The risk factors affecting outcome include pre-downstaging alpha-fetoprotein values, delta alpha-fetoprotein values, disappearance of portal vein tumor thrombosis on imaging and meeting the Milan criteria or not after downstaging. For hepatocellular carcinoma with portal vein tumor thrombosis, downstaging procedure with liver transplantation in mind would be helpful. If the reaction of the downstaged tumor is good, liver transplantation may be performed.
format Online
Article
Text
id pubmed-10035684
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Liver Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-100356842023-06-28 Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis Kim, Sang Jin Kim, Jong Man J Liver Cancer Review Article Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Recently, various studies on locoregional therapies for downstaging followed by living donor liver transplantation reported inspiring overall survival and recurrence-free survival of patients. These downstaging procedures included three-dimensional conformal radiation therapy, trans-arterial chemoembolization, stereotactic body radiation therapy, trans-arterial radioembolization, hepatic arterial infusion chemotherapy and combinations of these therapies. Selection of the optimal downstaging protocol should depend on tumor location, biology and background liver status. The risk factors affecting outcome include pre-downstaging alpha-fetoprotein values, delta alpha-fetoprotein values, disappearance of portal vein tumor thrombosis on imaging and meeting the Milan criteria or not after downstaging. For hepatocellular carcinoma with portal vein tumor thrombosis, downstaging procedure with liver transplantation in mind would be helpful. If the reaction of the downstaged tumor is good, liver transplantation may be performed. Korean Liver Cancer Association 2021-09 2021-09-02 /pmc/articles/PMC10035684/ /pubmed/37383081 http://dx.doi.org/10.17998/jlc.2021.03.17 Text en Copyright © 2021 by The Korean Liver Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kim, Sang Jin
Kim, Jong Man
Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
title Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
title_full Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
title_fullStr Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
title_full_unstemmed Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
title_short Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
title_sort liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035684/
https://www.ncbi.nlm.nih.gov/pubmed/37383081
http://dx.doi.org/10.17998/jlc.2021.03.17
work_keys_str_mv AT kimsangjin livertransplantationforhepatocellularcarcinomawithportalveintumorthrombosis
AT kimjongman livertransplantationforhepatocellularcarcinomawithportalveintumorthrombosis